Clinical and experimental studies have suggested that unfractionated heparin (UFH) effects
malignancy progression. We reviewed all published clinical reports concerning the effects of …

Background: Low‐molecular‐weight heparins (LMWH) have an antitumor effect in vitro and
in experimental animal models of malignancy. Retrospective data suggest that it might …

Background Tumors may exploit the coagulation system to enhance the survival and
dissemination of cancer cells. Some studies have suggested that heparin and low molecular …

Work with low-molecular-weight heparins (LMWHs) continues to provide suggestions for
survival advantages among patients with cancer diagnoses. Momentum is building in …

Background Low molecular weight heparins (LMWH) are often used as a first-line therapy
for the prevention of thrombosis in cancer patients. Preclinical evidence from animal models …

Background: Heparin has been the main subject of intensive investigation and clinical use
because of its therapeutic anticoagulant properties. It also exhibits many other biological …

OBJECTIVE To prospectively assess whether low-molecular-weight heparin (LMWH)
provides a survival benefit in patients with advanced cancer. PATIENTS AND METHODS …

BACKGROUND: Low-molecular-weight heparin (LMWH) has an anti-tumour effect in-vitro
and in animal models of malignancy; however, the evidence from clinical trials is …

Heparin has been the subject of intensive investigation for decades by both basic and
clinical scientists because of its usefulness as a therapeutic anticoagulant (1). In addition to …

The influence of unfractionated heparin (UFH) and other anticoagulants on the spread of
cancer has been reported since the early 1960s. 1 However, clinical studies investigating …